[1] He S, He F. Predictive model of portal venous system thrombosis in cirrhotic portal hypertensive patients after splenectomy[J]. Int J Clin Exp Med, 2015, 8(3): 4236-4242.
[2] 吴建顺, 李强, 吴贞. 生长抑素联合前列地尔治疗重症急性胰 腺炎的效果评价[J]. 转化医学电子杂志, 2015, 2(3): 52-53.
[3] 杨科, 杨启. 奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征的疗效[J]. 世界华人消化杂志, 2014, 22(20): 2942-2945.
[4] Pan X N, Zheng L Q, Lai X H. Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis[J]. World J Gastroenterol, 2014, 20(38): 14051-14057.
[5] Simillis C, Robertson F P, Afxentiou T, et al. A network meta-analysis comparing perioperative outcomes of interventions aiming to decrease ischemia reperfusion injury during elective liver resection[J]. Surgery, 2016, 159(4): 1157-1169.
[6] 高咏梅, 刘云峰, 姚金锋, 等. 前列地尔脂微球注射液对肝硬化门静脉高压患者血管活性物质的影响及意义[J]. 河北医药,2015, 37(5): 707-708.
[7] 李光明, 范建高. 2010年欧洲肝病学会肝硬化腹水、自发性细菌性腹膜炎、肝肾综合征指南解读[J]. 中国肝脏病杂志(电子版),2011, 3(3): 40-42.
[8] Kornberg A, Witt U, Kornberg J, et al. Treating ischaemia reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation[J]. Alimentary pharmacology & therapeutics, 2015, 42(9): 1101-1110.
[9] 李慧丽, 卢雪峰, 李娜. 恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察[J]. 临床肝胆病杂志, 2016, 32(2): 292-295.
[10] Akere A, Akande K O. Upper gastrointestinal endoscopy in patients with liver cirrhosis: Spectrum and prevalence of lesions[J]. Annals of Tropical Medicine and Public Health, 2016, 9(2): 112.
[11] Feldheiser A, Braicu E I, Bonomo T, et al. Impact of ascites on the perioperative course of patients with advanced ovarian cancer undergoing extensive cytoreduction: results of a study on 119 patients[J].International Journal of Gynecological Cancer, 2014, 24(3): 478-487.
[12] Bernsmeier C, Singanayagam A, Patel V C, et al. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure[J]. Immunotherapy, 2015, 7(6): 641-654.
[13] 郑建敏. 替比夫定与前列地尔联和治疗慢性乙型肝炎肝硬化的临床疗效观察[J]. 现代实用医学, 2014, 26(6): 722-724.
[14] Chen C, Chen R P, Lin H H, et al. Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites[J]. World journal of gastroenterology, 2016, 22(12): 3363.
[15] Marks E I, Yee N S. Molecular genetics and targeted therapeutics in biliary tract carcinoma[J]. World journal of gastroenterology, 2016, 22(4): 1335. |